Alessandro Martorana, Associate Professor in Neurology
Primary tabs
JAD profile
Associate Editor
Term Expiration:
12/31/2024
Affiliation(s):
University of Rome Tor Vergata
ORCID URL:
Areas of Interest:
dementia, biomarkers, neurotransmission, dopamine, synaptic plasticity
Biography & Research:
Born in Palermo on November 05, 1969.
1994: Degree in Medicine and Surgery at Univeristà degli Studi di Palermo, score: 1110/110 cum laude.
1999: Board certification in Neurology at the University of Rome "Tor Vergata", score: 70/70 cum laude.
1999-2000: Post-doc fellowship at the MRC Neuropharmacology Anatomy Unit, University of Oxford (UK) under the supervision of Prof. J.Paul Bolam.
2000-2003: PhD in Neuroanatomy of the Basal Ganglia at the Rome University Tor Vergata, tutor Prof. Paolo Calabresi.
2003-2016: Assistant Professor at the Memory Clinic, System Medicine Department, University of Rome Tor Vergata. He heads and works at the Memory clinic-Neurology Unit of the Rome University Tor Vergata.
2018-Associate Professor in Neurology at Rome University Tor Vergata, Rome –Italy
2018- Head of the Memory Clinic System Medicine Department, University of Rome Tor Vergata.
His scientific activity is documented by several papers published on international journals with referees. He qualified his activity in clinical and laboratory fields. Laboratory interests are based on his experience in neuroanatomical field with expertise in light and electron microscopy. He focused his research on plastic changes and remodeling occurring in basal ganglia nuclei in different laboratory models of neurodegenerative disorders like Huntington's and Parkinson's diseases, and also in models of Multiple Sclerosis.
His main clinical interest his directed to diagnosis and treatment of Alzheimer's dementia. He oriented his research in the study of cerebrospinal fluid biomarkers (Aβ ,t-Tau and p-Tau) their usefulness and limits in the diagnosis and treatment of Alzheimer’s dementia. Recently he also developed interest in understanding of mechanisms of synaptic plasticity impairment using electrophysiological tools (trancranial magnetic stimulation, evoked potentials) and their relationship with cerebrospinal fluid biomarkers.
He worked as study coordinator in several clinical trials on Alzheimer’s dementia (Gantenerumab, Rivastigmine, Donepezil, Memantine) and dedicated most of his clinical interest on the effects of acetylcholinesterase inhibitors in patients with different forms of dementia.
